SCHEMBL3420747

SCHEMBL3420747

C[C@@H](CC(=O)Nc1sc2c(c1C#N)CCN(C(=O)CCc1ccccn1)C2)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.53
KMT2A Q03164 7/20 0.53
L3MBTL1 Q9Y468 1/20 0.49
STAT3 P40763 2/20 0.49
MAPK10 P53779 2/20 0.47
MAPK9 P45984 1/20 0.47
CRHBP P24387 1/20 0.44
CRHR2 Q13324 1/20 0.44
GRM1 Q13255 4/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
BLM P54132 1/20 0.43
KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3420743 1.00 MEN1 (0.53) MEN1KMT2AL3MBTL1STAT3MAPK10
SCHEMBL3423140 0.92 MEN1 (0.56) MEN1KMT2AL3MBTL1STAT3MAPK10
SCHEMBL3423136 0.92 MEN1 (0.56) MEN1KMT2AL3MBTL1STAT3MAPK10
SCHEMBL2962924 0.91 MEN1 (0.54) MEN1KMT2AL3MBTL1STAT3MAPK10
SCHEMBL2962929 0.91 MEN1 (0.54) MEN1KMT2AL3MBTL1STAT3MAPK10
SCHEMBL2954864 0.90 MEN1 (0.46) MEN1KMT2AL3MBTL1STAT3MAPK10
SCHEMBL2954859 0.90 MEN1 (0.46) MEN1KMT2AL3MBTL1STAT3MAPK10
SCHEMBL2891592 0.90 MEN1 (0.51) MEN1KMT2AL3MBTL1STAT3MAPK10
SCHEMBL2962641 0.89 MEN1 (0.48) MEN1KMT2AL3MBTL1STAT3MAPK10
SCHEMBL2962643 0.89 MEN1 (0.48) MEN1KMT2AL3MBTL1STAT3MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090258873-A1 Novel tetrahydropyridothiophenes PEKARI KLAUS 2009-10-15 US claimed
US-20080206258-A1 Novel Tetrahydropyridothiophenes NYCOMED GMBH (DE) 2008-08-28 US claimed
EP-1896484-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER Nycomed GmbH (DE) 2008-03-12 EP claimed
WO-2006125813-A2 TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER NYCOMED GMBH (DE) 2006-11-30 WO claimed
US-7714136-B2 Tetrahydropyridothiophenes 4SC AG (DE) 2010-05-11 US disclosed
US-20090258873-A1 Novel tetrahydropyridothiophenes PEKARI KLAUS 2009-10-15 US disclosed
US-20080206258-A1 Novel Tetrahydropyridothiophenes NYCOMED GMBH (DE) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080206258-A1 Novel Tetrahydropyridothiophenes BAX, BCL2, CCAR2 MEN1 4691/4885KMT2A 2644/4885L3MBTL1 2416/4885
US-20090258873-A1 Novel tetrahydropyridothiophenes BAX, BCL2, CCAR2 MEN1 4735/4885KMT2A 2418/4885L3MBTL1 2312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.